TY - JOUR
T1 - Effect of a Somatostatin Analogue on Trophic Hormone Levels in Acromegalic Patients with Elevated hGH after Adrenomectomy and Treatment with Bromocriptine
AU - Szilágyi, G.
AU - Irsy, G.
AU - Góth, M.
AU - Szabolcs, I.
AU - Coy, D. H.
AU - Comaru-Schally, A. M.
AU - Schally, A. V.
PY - 1984/10
Y1 - 1984/10
N2 - Five female acromegalic patients who had undergone surgical adenomectomy, but still had elevated hGH serum levels, were treated with bromocriptine, 5-15 mg daily, for at least 4 months without a satisfactory response. In an attempt to lower serum hGH levels, p-NH2-Phe4-D-Trp8-somatostatin was administered, 100 μg as an i.v. bolus, followed by infusion of 250 μg over a 4 hour period. The analogue decreased hGH levels by about 50% in 3 out of 5 patients, both during bromocriptine treatment and also in its absence. Of the remaining two patients, one showed a decrease in hGH levels in response to the analogue only during bromocriptine treatment and the other only without it. Saline infusion after bromocriptine administration did not induce a decrease in hGH levels in three of these patients. Somatostatin analogue caused a fall in serum insulin levels in all but one patient, who had diabetes mellitus and in whom serum insulin was undetectable. Both hGH and insulin levels showed a significant rebound after infusion of the analogue, but returned to basal levels within 24 hours. Prolactin did not change during the analogue infusion in 4 patients with normal PRL levels. However, in one patient in whom prolactin and hGH levels were elevated during bromocriptine treatment, the infusion of somatostatin analogue decreased both hormones. The analogue induced no changes in serum TSH, FSH and LH levels of any of the patients.
AB - Five female acromegalic patients who had undergone surgical adenomectomy, but still had elevated hGH serum levels, were treated with bromocriptine, 5-15 mg daily, for at least 4 months without a satisfactory response. In an attempt to lower serum hGH levels, p-NH2-Phe4-D-Trp8-somatostatin was administered, 100 μg as an i.v. bolus, followed by infusion of 250 μg over a 4 hour period. The analogue decreased hGH levels by about 50% in 3 out of 5 patients, both during bromocriptine treatment and also in its absence. Of the remaining two patients, one showed a decrease in hGH levels in response to the analogue only during bromocriptine treatment and the other only without it. Saline infusion after bromocriptine administration did not induce a decrease in hGH levels in three of these patients. Somatostatin analogue caused a fall in serum insulin levels in all but one patient, who had diabetes mellitus and in whom serum insulin was undetectable. Both hGH and insulin levels showed a significant rebound after infusion of the analogue, but returned to basal levels within 24 hours. Prolactin did not change during the analogue infusion in 4 patients with normal PRL levels. However, in one patient in whom prolactin and hGH levels were elevated during bromocriptine treatment, the infusion of somatostatin analogue decreased both hormones. The analogue induced no changes in serum TSH, FSH and LH levels of any of the patients.
KW - Acromegaly growth hormone
KW - Bromocriptine
KW - Prolactin
KW - Somatostatin analogue
UR - http://www.scopus.com/inward/record.url?scp=0021710043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021710043&partnerID=8YFLogxK
U2 - 10.1055/s-0029-1210386
DO - 10.1055/s-0029-1210386
M3 - Article
C2 - 6543182
AN - SCOPUS:0021710043
VL - 84
SP - 190
EP - 196
JO - Experimental and Clinical Endocrinology and Diabetes
JF - Experimental and Clinical Endocrinology and Diabetes
SN - 0947-7349
ER -